FMP

FMP

Enter

NVV1.F - Novavax, Inc.

photo-url-https://financialmodelingprep.com/image-stock/NVV1.F.png

Novavax, Inc.

NVV1.F

XETRA

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

9.03 EUR

-0.234 (-2.59%)

About

ceo

Mr. John Charles Jacobs M.B.A.

sector

Healthcare

industry

Biotechnology

exchange

XETRA

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical...

CIK

N/A

ISIN

US6700024010

CUSIP

N/A

Address

21 Firstfield Road

Phone

240 268 2000

Country

US

Employee

1,543

IPO Date

Feb 1, 2001

NVV1.F Financial Summary

CIK

-

Exchange

XETRA

Industry

Biotechnology

Sector

Healthcare

CUSIP

-

ISIN

US6700024010

Country

US

Price

9.03

Beta

2.03

Volume Avg.

5.78k

Market Cap

1.45B

Shares

-

52-Week

3.33-23.93

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.72

P/B

-

Website

https://www.novavax.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest NVV1.F News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep